FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 575 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Urine test for bladder cancer being developed July 2, 2021 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Load more HOT NEWS An Oncology Hospital at Home Model of Acute Care Shows Promise First Prospective Description of Familial EGFR-mutated Lung Cancer FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... Talazoparib Plus Enzalutamide Improves rPFS Over Placebo Plus Enzalutamide in First-Line...
